AFP and cryohydrocytosis: Although higher than the PPV observed for AFP (11.9% in the CHB cohort and 9.49% in the CHC cohort), the PPV for PIVKA-II (15.18% and 16.23% in the CHB and CHC cohorts, respectively) remains suboptimal, highlighting the limitations of relying on a single biomarker for early detection.